Luye Pharma Group Ltd. Stock price

Equities

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:23 2024-03-19 am EDT 5-day change 1st Jan Change
2.93 HKD -1.01% Intraday chart for Luye Pharma Group Ltd. -1.68% -21.45%

Financials

Sales 2023 * 6.08B 845M 6.61B Sales 2024 * 6.87B 954M 7.46B Capitalization 10.25B 1.42B 11.14B
Net income 2023 * 584M 81.12M 634M Net income 2024 * 591M 82.1M 642M EV / Sales 2023 * 2.29 x
Net Debt 2023 * 3.67B 510M 3.99B Net Debt 2024 * 3.66B 509M 3.98B EV / Sales 2024 * 2.03 x
P/E ratio 2023 *
16.8 x
P/E ratio 2024 *
16.4 x
Employees 5,005
Yield 2023 *
-
Yield 2024 *
-
Free-Float 51.9%
More Fundamentals * Assessed data
Dynamic Chart
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3% MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong CI
Luye Pharma Group Ltd. Announces Board Changes CI
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China CI
Luye Pharma Files New Drug Application in US for Schizophrenia Medication MT
More news
1 day-1.01%
1 week-1.68%
Current month+1.38%
1 month+9.33%
3 months-16.29%
6 months-12.54%
Current year-21.45%
More quotes
1 week
2.90
Extreme 2.9
3.20
1 month
2.60
Extreme 2.6
3.20
Current year
2.34
Extreme 2.34
3.77
1 year
2.34
Extreme 2.34
4.05
3 years
1.88
Extreme 1.88
5.84
5 years
1.88
Extreme 1.88
7.90
10 years
1.88
Extreme 1.88
11.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 03-07-01
President 58 94-06-07
Corporate Officer/Principal 60 94-06-07
Members of the board TitleAgeSince
Director/Board Member 65 94-06-07
President 58 94-06-07
Chief Executive Officer 59 03-07-01
More insiders
Date Price Change Volume
24-03-19 2.93 -1.01% 4 194 500
24-03-18 2.96 -3.27% 7,752,500
24-03-15 3.06 0.00% 6,518,054
24-03-14 3.06 +1.32% 16,288,500
24-03-13 3.02 +1.34% 4,636,000

Delayed Quote Hong Kong S.E., March 19, 2024 at 03:59 am EDT

More quotes
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company's main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer's disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.725 CNY
Average target price
3.166 CNY
Spread / Average Target
+16.19%
Consensus
  1. Stock
  2. Equities
  3. Stock Luye Pharma Group Ltd. - Hong Kong S.E.